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ABSTRACT
In this review will be underlined two simple ideas of potential interest for the 
design of cancer immunotherapies. One concerns the importance of kinetics, with the 
key notion that a single cause may trigger two opposite effects with different kinetics. 
The importance of this phenomenon will be underlined in neurobiology, transcription 
networks and the immune system. The second idea is that efficient immune responses 
have been selected against pathogens, throughout evolution. They are never due to 
a single cell type, but always require multiple, complex cellular cooperations. One 
cannot recognize this fact and persist in the presently dominant T-cell centered view 
of cancer immunotherapies. Suggestions will be made to incorporate these simple 
ideas for improving these therapies.
FROM KINETICS AND CELLULAR 
COOPERATIONS TO CANCER 
IMMUNOTHERAPIES
Twenty years ago, only a minority of immunologists 
and oncologists considered immunotherapy to be an 
effective strategy for cancer treatment. The situation has 
since radically changed, and several strategies are being 
used.
The anti-tumoral toxicity of antibodies 
targeting tumor [1] or vascular epitopes [2] is exerted 
via components of the immune system (NK cells, 
macrophages, or complement). Several of these antibodies 
have yielded clinical benefits, namely those used to treat 
blood cancers [3]. 
Other promising results have recently been obtained 
with antibodies directed against PD-1 and/or CTLA-4, i.e., 
T-cell surface molecules that exert inhibitory effects on 
T-cell responses, [4]. For instance, in a phase III clinical 
trial [5], 405 patients were treated either with an anti-PD-1 
antibody or with investigator’s choice of chemotherapy. 
Confirmed objective responses were reported in 32% of 
the patients treated with the anti-PD-1, versus 11% in the 
chemotherapy group. However, given the large percentage 
of patients displaying no response to treatment, real 
improvements to such approaches are required.
Antibody treatments activating T cells represented 
new variations of older trials designed to trigger antigen-
specific T cells through different types of vaccination, 
including vaccination with antigen-loaded dendritic cells 
[6] or long peptides [7].
Another T cell-based cancer immunotherapy to 
attract attention recently is the adoptive transfer of patient 
T cells engineered to express CARs (chimeric antigenic 
receptors). These receptors are surrogate TCRs with a 
high affinity for a selected tumor antigen and boosted 
signaling activity. After their transfection and in vitro 
expansion, these cells are transferred to the patient. 
Impressive results have been obtained for a few B-cell 
malignancies refractory to all previous treatments. Thus, 
in a recent study [8], 14 patients with refractory chronic 
lymphocytic leukemia were repeatedly treated with CAR 
T cells targeting CD19, and complete or partial remissions 
were observed in 8 of them (57%). However, this approach 
has proved unsuccessful in the treatment of other blood 
cancers, and has never been shown to work for solid 
tumors [9], due to insufficient tumor infiltration and/or 
excessive nonspecific toxicity. Finally, general stimulation 
of the immune system with immunostimulatory cytokines, 
such as IL-2 (Royal 1996), IFNα [10], or GM-CSF [11], 
has also been tested, but with disappointing results and 
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high levels of toxicity. 
A major objection to these therapies is that they 
do not take into account two major features of efficient 
natural immune responses: their specific kinetic 
characteristics and the well documented cooperation 
between cells. Efficient immune system responses to 
infection are invariably based on complex cooperation 
between different cells rather than on the action of a single 
cell type. Strangely, the importance of this cooperation 
between cells is largely overlooked in oncoimmunology, 
where the prevailing view is highly T cell-centered.
Let us start with the lack of attention paid to 
kinetics in immunology, with few exceptions (see e.g. 
[12][13][14]). This may reflect the strong historical link 
with medicine, and with the medical custom of detailed 
classifications. This trend has been amplified by the power 
of flow cytometry, allowing the definition of an ever 
increasing number of cell subtypes. However, the time-
dependence of the subpopulations is all too often ignored, 
with cell populations treated as if they were stable, which 
they are not. 
The importance of kinetics is better taken into 
account in other biological fields, such as enzymology and 
neurobiology, probably thanks to a tradition of dialog with 
physicists and biophysicists. A brief detour through the 
field of neurobiology will help us to stress the importance 
of kinetics in analyzing functions. It will allow to present 
a general notion of the utmost importance: a single cause, 
or stimulus, may trigger opposite effects with different 
kinetics. We will use a few examples to illustrate and 
discuss this notion.
Voltage-dependent Na+ channels, an archetypal 
example of a biological structure in which one 
stimulus triggers two opposite, successive effects
Information travels along nerves in the form of 
action potentials. These action potentials are changes in 
the potential of the membrane, which locally loses the 
negativity of its resting state to become positive for one or 
a few milliseconds. Action potentials travel rapidly (1-100 
m/s), reflecting the local propagation of a transient wave 
of Na+ channels opening. These channels are voltage-
dependent and the initial membrane depolarization triggers 
two opposite consequences: the opening of the channel 
(activation), followed by its closure (inactivation) (Figure 
1A). Only one effect is initially visible, but this effect is 
then fully masked by the second effect. This sequence 
translates a step stimulus into a response resembling the 
derivative of the stimulus: the Na+ channels open only 
immediately after the onset of the depolarizing stimulus. 
A key feature of this system is that the opening of some 
Na+ channels upon cell depolarization leads to the opening 
of other Na+ channels. This positive feedback underlies the 
kinetically explosive nature of action potential, which is 
brought to an end by inactivation.
Desensitization of receptors to neurotransmitters 
and other ligands, a second example of a single 
cause triggering two opposite, successive effects
At the neuromuscular synapse, information is 
transmitted from a neuron to a muscle cell through the 
release of acetylcholine (ACh), which binds to receptors 
on the muscle, triggering two different events: opening 
of the nicotinic receptor-channel (AChR), followed by 
receptor desensitization, leading to channel closure. 
The second of these phenomena develops more slowly 
than the first, so we observe a transient opening of the 
AChR (Figure 1B). Initial activation on ligand binding, 
followed by receptor desensitization, is commonly 
observed not only with neurotransmitters, but also for 
chemokine receptors. This sequence of events explains 
the transient nature of most responses to neurotransmitters 
and chemokines. As shown in Fig 1, in these biphasic 
responses, one can distinguish three states: resting, 
activated, and desensitized/inactivated.
Adaptation: a feature common to sensory systems, 
transcription networks and the immune system
The kinetic phenomena described above raise 
questions concerning adaptation and, thus, sensitivity to 
discontinuities. According to Weber’s law, the smallest 
difference between two stimuli that can be discriminated 
by the sensory system is proportional to the magnitude of 
the stimulus. In other words, our sensory systems do not 
discriminate between absolute values; instead they detect 
fold-changes. When the visual system is stimulated with 
a constant level of light, it rapidly adapts such that the 
system detects only variations above this level, provided 
that these variations are large enough relative to this 
new level. In practice, variations of a few percent above 
the level of steady stimulation can be detected, whereas 
smaller variations cannot. This property underlies the 
ability of sensory systems to span huge variations of 
stimulus intensity. 
Light may be detected over nine orders of magnitude 
: we can detect single photons in some conditions, and 
variations exceeding hundreds of millions of photons 
in others. This exceptional performance is dependent 
on a complex neuronal network and a combination of 
spatiotemporal mechanisms, including adaptation to 
background light levels.
This “fold-change detection” paradigm applies 
not only to sensory systems, but also to transcription 
networks. Theoretical backgrounds [15] have been used 
to demonstrate how an incoherent feedforward loop, 
in which an activator switches on both a gene and its 
repressor, can achieve this goal. If a single cause (the 
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Figure 1: A single stimulus may elicit two opposite, successive responses. Left: experimental data. Right: schematic models. 
A. In neurons, membrane depolarization (dark blue) elicits a transient inward current (red), due to the entry of Na+ ions into the cell. The 
channels, which are initially closed (1) first open (2) and are then inactivated/closed (3) by depolarization. The “ball and chain” model of 
inactivation is shown [51] B. Sustained ACh application triggers a transient inward current in the cell (muscle or neuron). Following ACh 
binding, nicotinic receptor channels first open and are then massively desensitized/closed. The desensitized conformation of AChR may 
exist in the presence and absence or bound ACh [52]. C. A transcription factor X immediately activates a target Z, and slowly activates 
a repressor Y, which then fully inhibits the target. In a such a system, activation of the target is transient (adapted from [15]). The model 
illustrates the fold-change paradigm: the same target response may be observed with stimuli of different intensities, the two outputs 
perfectly overlap.
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activator) triggers two effects, with activation slightly 
preceding full inhibition, then the transcriptional response 
can be considered to be the derivative of the stimulus. This 
model can be used to interpret the fold-detection paradigm 
(Figure 1C).
As discussed in more detail below, the immune 
system also adapts to chronic or constant stimulation. As a 
result, the immune system responds only to discontinuities 
[16][17], a feature of fundamental importance for its 
functioning. The sudden effraction of viruses or bacteria 
at the periphery of the organism (skin, mucosa) may be 
detected as discontinuities by a whole set of molecules 
present at the surface of cells from both the innate and 
adaptative immune systems. Thus, adaptation/sensitivity 
to discontinuities is a very general phenomenon, with 
features specific to each system. In particular, even 
though the immune system has to detect variations in its 
environment, it differs from sensory systems in one major 
aspect. The visual sensory system response to a single 
stimulus, light, which has a limited number of features 
(intensity, color, shape, velocity). The system is clearly 
structured along an axis extending from the photoreceptors 
to the brain. The immune system has no equivalent central 
structure. The detection system and information exchanges 
are distributed throughout the body and the system can 
detect thousands of different sorts of stimuli, which cannot 
be quantified in a simple manner. The fold-detection 
paradigm does not therefore apply to this system. 
Borders of the immune system
We now need to define the immune system. Any 
such definition is controversial by its very nature, because 
the immune system is nothing but a concept that has 
changed during the history of science. In the 1970s and 
1980s, the most important feature of the immune system 
appeared to be its ability to make antibodies. The focus 
has since changed, and many immunologists now have 
a T cell-centered view of immunology. This focus will 
certainly change again in the future. 
The immune system considerably evolved from 
primitive organisms, in which macrophages (Mφ) or their 
equivalent were the major cells involved in defense against 
pathogens, to vertebrates, which have many more types 
of immune cells, including antigen-specific T and B cells 
[18]. As our aim here is to find ways of improving cancer 
immunotherapy, we will focus on the mammalian immune 
system. Mφ pose a major problem in the definition of the 
mammalian immune system, because these cells are not 
only anti-infectious agents, they are also indispensable 
for the development of the organism [19]. They are 
required to eliminate dead cells, which are produced in 
large numbers in developing organisms, and to control the 
development of the stroma which envelops the organs in 
normal conditions or after a lesion. They remain essential 
for the maintenance of adult tissues. 
The definition of the immune system is further 
complicated by the abundant commensal flora present in 
the intestine. This has led some authors to consider the 
superorganism formed by the organism and its flora, and to 
suggest that the main function of the immune system is to 
maintain the homeostasis of this superorganism [20]. Such 
a broad definition of a homeostatic immune system may be 
considered too vague to be particularly useful, especially 
when considering evolutionary pressures. A definition that 
is more helpful as a conceptual tool is that the mammalian 
immune system consists of a set of different cells (B and T 
lymphocytes, NK cells, neutrophils, Mφ, dendritic cells) 
and of the molecules they secrete that may act collectively 
to exert efficient anti-infectious effects. Consistent with 
this definition is the recognition that pressures on the 
immune system during the course of evolution have 
optimized the efficacy of these anti-infectious effects. As 
discussed below, the immune response always includes a 
reactive, acute phase followed by a return of the immune 
system to an equilibrium.
The immune system may therefore be seen as a 
major, but not exclusive, subset of a larger anti-infectious 
device that also makes use of mechanisms present in all 
cell types. Almost all cells can detect the presence of 
viral double–stranded RNA and secrete IFNα/β upon 
viral infection. Similarly, upon bacterial infection, any 
cell type (including, in particular, mucosal epithelial 
cells) can detect the presence of the bacteria and trigger 
NF-κB-dependent IL-8 secretion, thereby alerting 
neutrophils [21]. Such ubiquitous triggering mechanisms 
play a key role in the anti-infectious device, but are not 
specific to the immune system. More precisely, IFNα/β 
can initially be produced, in small quantities, by any cell 
type. However, the immune system contains a single cell 
type (plasmacytoid dendritic cells) able to produce this 
compound in huge amounts [22]. IFNα/β may therefore 
be considered to be both out and in the immune system.
With our definition of the immune system (a set of 
cells and the molecules they secrete to fight infection), 
Mφ are both part of and outside the immune system. 
Conceptually, they lie at the borders of the immune system 
and, physically, they are frequently particularly abundant 
at the periphery of organs. 
Key phenomena take place at these blurred 
borders, particularly in the intestine, the largest interface 
between the interior and exterior of the body. There is 
an extraordinary concentration of bacteria at this border, 
with which the mammalian host must establish a well-
controlled dialog. Immune cells are highly abundant at this 
interface, at which the immune system encounters some of 
its trickiest challenges: active defense against pathogens 
without unnecessary overreaction that might damage 
normal tissue or the associated commensal organisms 
essential for both food assimilation and for preventing the 
development of other toxic bacteria. Indeed, the presence 
and abundance of non-toxic intestinal bacteria contribute 
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to the defense of the body against potentially toxic bacteria 
[23]. Like the immune system, commensals constitute 
another subset of a larger anti-infectious device.
A key constraint acting on the immune system is that 
it must not trigger autoimmune attack. This constraint has 
led to the selection of processes to prevent damage to self. 
An economical definition of the self is what is permanent 
in an organism or at least what changes only slowly. 
However, self is not a notion easy to define. In particular, 
commensals could be viewed both as self and as non-
self. They are part of self because they are permanently 
present in the intestine, in very large numbers, and play a 
key role in our homeostasis. But they can also be seen as 
non-self because we are not born with them, they can have 
hosts other than humans and the evolutionary pressures 
acting on them are different from those acting on humans. 
We can therefore consider them to be part of a self with 
blurred borders. 
The notion of self/non-self is irrelevant at the 
level of single cells. T cells are not activated by non-self 
ligands, but simply by a sudden change in the amount of a 
recognized ligand. The concept of self becomes important 
and useful only as an emergent property of a multicellular 
structure, the organism, which includes permanent, or at 
least slowly changing, components.
Importance of kinetics in immunology, as 
illustrated by the case of viral infections
Viral infection rapidly triggers a sequence of events. 
As described above, virus detection leads first to a non-
immune response: any cell infected with a virus produces 
IFNβ and IFNα, and shuts down its own translation 
processes and those in neighboring cells. Sentinel cells 
(resident Mφ and innate lymphoid cells) raise the alert, 
triggering the recruitment of inflammatory monocytes/
Mφ, thereby initiating the immune response. By rapidly 
ingesting infected cells, Mφ make an immediate 
contribution to viral clearance. Together with dendritic 
cells (DC), they also recruit T cells, and present them viral 
antigens, leading to the initiation, several days later, of 
a T-cell response. Only then do the CD8 T cells become 
key antiviral actors. Beforehand, they have an absolute 
requirement for the initial help of Mφ, DC, and CD4 
T cells, both for their initial recruitment and for their 
subsequent activation. CD4 T cells also play a key role 
in the development of antigen-specific B cells, which 
differentiate into plasmocytes and produce antibodies 
(some of which are, hopefully, neutralizing). The rare CD8 
T-cell clones able to recognize viral antigens at the surface 
of DC then proliferate very rapidly. A detailed study of 
the kinetics of this response in individuals vaccinated 
against yellow fever [24] showed that specific anti-viral 
T cells took several days to reach large numbers, with a 
peak about two weeks after infection. If these T cells kill 
infected cells efficiently enough then the spread of the 
virus is halted.
Even if it takes days and must be preceded by an 
innate response, the development of the T-cell response 
is accelerated by positive feedback mechanisms. The 
clonal exponential expansion of virus-specific T cells is 
characterized by a constant acceleration, as in a positive 
feed-back system. The proliferating T cells then produce 
a growth factor, IL-2, and express CD25, the high-affinity 
receptor for IL-2. This triggers an autocrine and paracrine 
feedback loop for T-cell expansion and differentiation.
The expansion of the virus-specific T-cell population 
is followed by a phase of contraction. This population 
rapidly decreases in size, through a series of mechanisms, 
the first of which is the fratricide phenomenon of FasL-
dependent AICD (activation-induced cell death). Other T 
cells die by starvation. They require the growth/survival 
factor IL-2 if they are to stay alive, but IL-2 production 
by T cells is only transient, peaking in vivo, about six days 
after the recently activated naive murine T cells begin 
to respond (this time lag is only two days for memory T 
cells) [25]. Similarly, CD25 is expressed only transiently 
on activated T cells. Its expression peaks one day after 
the initiation of the response, and it disappears within 
one week [26]. With insufficient CD25 and IL-2, the 
activated T cells die. As IL-2 is consumed by T cells, an 
overpopulation of T cells results in a shortage of available 
IL-2. This IL-2-dependent control of the size of the T cell 
population is further tuned by specialized T cells which 
have a strong impact on the available IL-2. Thus, Th2 CD4 
T cells act as IL-2 producers, a production that may benefit 
T cells that are not producing IL-2. Amongst the pure 
IL-2 consumers, regulatory T cells completely depend 
upon other T cells for the IL-2 that they consume. When 
their number is large, they act as a sink for IL-2 and thus 
accelerate the shrinkage of the global IL-2-dependent T 
cell population.
In addition to the mechanisms contributing to the 
collapse of the recently expanded T-cell population, there 
are mechanisms decreasing the functional efficiency 
of the remaining T cells, due to the expression of 
inhibitory receptors, such as PD-1 and CTLA-4 [27]. 
As PD-1 expression begins one day after the onset of 
CD25 expression, it should be considered a marker of 
activated T cells, not only of inactivated or desensitized 
cells. An understanding of the kinetics of expression of 
molecules such as CD25, IL-2, PD-1 is essential if we are 
to comprehend the functional state of these cells.
After the contraction phase, the immune system 
does not return to its initial state, because a new, small 
population of long-lived memory T and B cells (antiviral 
in this case) has appeared, which will ensure a faster 
response to subsequent viral attacks. We have considered 
the case in which the contraction of the T-cell population 
follows similar kinetics to the disappearance of the 
virus. However, if the response is not efficient and the 
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virus persists, the contraction phase and the generation 
of inhibitory receptors nevertheless occurs. It is not the 
elimination of the virus that stops the immune response. 
The expansion-contraction sequence is triggered right at 
the start of the infection. This is another example of the 
principle that a single cause may induce two opposite 
and successive effects. If the virus persists, the T cells 
remaining after the contraction phase are not memory T 
cells but dysfunctional T cells (sometimes called anergic, 
exhausted or desensitized). This state is not definitive. It 
can be reversed by the removal of chronic stimulation, 
when cells are maintained in culture for example [28].
These desensitizing mechanisms should not be 
viewed as a defect or problematic limitation of the 
efficacy of the T cell-mediated antiviral response. In the 
absence of such mechanisms, the overactivated immune 
system would cause off-target attacks on normal tissues, 
resulting in catastrophic autoimmunity. Indeed, despite 
these mechanisms, a number of autoimmune diseases are 
known to be triggered by viral infection [29]. It may seem 
strange that autoimmune diseases are often chronic when 
efficient antiviral responses are necessarily transient. One 
reason is that even though immune activity is not very 
efficient in chronic autoimmune diseases, its destructive 
consequences accumulate slowly and may be irreversible. 
Furthermore, autoimmune diseases are often not truly 
chronic, instead resulting from repeated transient attacks. 
Finally, autoimmune diseases are usually associated 
with local chronic inflammation, a process in which non 
immune cells, i.e., activated fibroblasts [30], play a major 
role. 
Thus, multiple mechanisms contribute to the fact 
that T cell-mediated immune responses to a viral attack 
are usually transient. 
The absence of an efficient antitumoral immune 
response is predictable
Let us summarize some of the conclusions reached 
so far. We have seen that, in many biological systems, 
a single cause can trigger two opposite and successive 
responses, with activation preceding marked inhibition. 
Such phenomena are general, applying to neuronal Na+ 
channels, neurotransmitters and chemokine receptors, 
transcription networks, and the immune system. Figure 
2 illustrates the striking similarity in the time course of 
action potentials and immune responses, over different 
time scales.
The functional consequences of this phenomenon 
are entirely system-dependent. In the immune system 
the specific features of these transient responses are as 
follows. First, as positive feedback mechanisms play 
an important role in accelerating and strengthening the 
initial response, inhibitory mechanisms are subsequently 
required to prevent an explosive, uncontrolled response. 
Second, the immune system, which is highly effective 
against pathogens, is very powerful, and this power 
poses a constant threat of bystander damage to self. A 
key feature of self being its permanence, an absence of 
response to sustained signals is required to avoid damage 
to what is permanent, to prevent autoimmunity. This may 
explain why repetitive stimulations of T cells, B cells or 
NK cells are integrated in chronic stimulations leading to 
anergy/desensitization. 
In humans, tumor development is thought to start 
very slowly, with an initial growth phase lasting for several 
years followed by a secondary acceleration in which 
all the controls have been removed and tumor growth 
becomes noticeable. A normal stromal environment limits 
tumor development [31]. At some time point, under the 
influence of tumor cells, the stroma may become activated 
and contractile, with serious consequences. Indeed, tumor 
growth requires not only multiple mutations in the tumor 
cells themselves, but also changes in their interactions 
with neighboring cells [32]. There may therefore be a 
switch in the function of the tumor-stroma border, from a 
tumor-controlling to a tumor-promoting role. The immune 
system also exerts an additional control, particularly for 
metastasis development, which is facilitated in the absence 
of CD8 T cells [33].
Thus, both normal stroma and immune cells may 
slow tumor development. With such slow kinetics (absence 
of discontinuity), an intense immune response cannot 
be triggered. If a weak, inefficient immune response is 
nevertheless transiently triggered, then the specific anti-
tumor cells become desensitized, because the tumor has 
become a permanent component of the organism, at the 
time scale of a lymphocyte (a few weeks or months). 
Even though the immune system is one of the systems 
limiting the occurrence of some cancers, the frequent lack 
of efficiency of anti-tumoral immune responses should not 
be viewed as a defect of the of the immune system, but an 
expected, normal feature of this system.
From anti-infectious to anti-tumoral immune 
responses
When comparing anti-infectious and anti-tumoral 
immune responses, a key question arises concerning 
the interactions between T cells and Mφ. The T cell-
centered view of cancer immunotherapy has recently been 
reinforced by the striking clinical trials mentioned at the 
beginning of this paper, with antibodies against PD-1 or 
CTLA-4 on the one hand, and T-cell CARs on the other. 
The spectacular results of these trials have bolstered the 
existing dogma: The T cells are the good guys against 
the tumor, we must simply give them more weapons to 
allow them to strike more forcefully. It’s just a question 
of intensity.
The other side of the coin is that Mφ are often 
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considered to be the bad guys: in many cases, their 
abundance in the tumor is correlated with a poor 
prognosis. The initiation and development of many 
cancers have been associated with chronic inflammation. 
Based on this observation, the prevailing view is that 
inflammation and inflammation-associated cells, such as 
Mφ, exert protumoral effects. 
Inflammation, like many other biological 
phenomena, is normally transient. It may have many 
possible origins — internal or external, microbial, physical 
or due to toxins — but it generally presents with a rapid 
onset followed by a phase of resolution [34]. Evolution 
has selected this acute, controlled inflammatory process 
to optimize the defense of the organism. The problem 
is that the resolution phase does not include the full 
adaptation/desensitization/anergy described above 
for other biological phenomena. As a result, chronic 
stimulation may lead to chronic inflammation, which 
may even become self-sustained after the cessation of a 
prolonged stimulus, because fibroblasts may have locally 
switched locally and permanently to an activated stated 
[30]. Chronic inflammation should not be confused with 
basal inflammatory tone, which is linked to the presence 
of the commensal flora [35] and keeps the immune system 
on alert without actually triggering a real, acute response, 
with positive and negative feedback. Mφ can contribute to 
both acute and chronic types of inflammation. In addition, 
independently of inflammation, they contribute to the 
development and maintenance of all tissues, including 
tumors. These characteristics have led to Mφ being seen 
as the bad guys by most oncoimmunologists (for a widely 
cited review, see [36]).
Ten years ago, Mφ were generally considered to be 
of two types, with M1 Mφ associated with inflammation, 
as opposed to M2 Mφ, which were considered responsible 
for anti-inflammatory responses [37]. Overall, the 
Figure 2: Transient nature of biological responses. A. Action potential B. Immune response. Adapted from [47]. Similar times 
courses with very different time scales.
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inflammation-Mφ association was considered to be 
pro-tumoral, particularly in the presence of B cells and 
antibodies contributing to this inflammation [38]. M1 
and M2 have since been recognized as the extremes in a 
spectrum of phenotypes, with the Mφ present in a tissue 
usually presenting mixed M1 and M2 features: the binary 
distinction is too simplistic [39]. In addition, several 
groups have shown that Mφ plasticity can be exploited 
for anti-tumoral purposes, through activation elicited by 
IFNγ, TLR agonists, and anti-CD40 antibodies (reviewed 
in [40]). However, this remains a minority view, with 
the prevailing dogma remaining that immunotherapy for 
cancer will be improved by the elimination of tumor-
associated Mφ. 
Making use of the anti-infectious immune response 
to fight cancer is an old idea that still deserves to be 
defended today. This was already the conviction of 
William Coley, at the end of the 19th century. Coley 
noticed a striking coincidence between major infections 
and subsequent “spontaneous” tumor regression [41]. For 
reasons that remain unclear, such regressions wer more 
frequently observed for sarcoma (of mesenchymal origin) 
than for carcinoma (of epithelial origin) [42]. Coley 
exploited this finding throughout his career, but very little 
research is carried out in this area today.
One of the very few clinical applications arising 
from Coley’s work is the intravesical injection of BCG 
(Bacillus Calmette-Guérin) for the treatment of bladder 
cancer. This approach works by triggering an intense 
immune response, beginning with massive neutrophil 
infiltration [43]. All attempts to extend this result to other 
cancers have failed, probably because the bladder is in 
the unusual position of being located within the body, but 
directly connected to the exterior. This specific location, 
at the border between the interior and exterior, makes 
it possible to introduce a very high concentration of 
attenuated but living bacteria, triggering an intense local 
immune reaction. The introduction of a similar number 
of bacteria directly into an irrigated organ would cause 
extensive damage and lead to dissemination of the bacteria 
throughout the body. 
Oncolytic viruses can also be used to exploit 
anti-infectious responses to fight cancer. These viruses 
present a marked tropism for tumor cells, in which they 
replicate more efficiently than in normal cells. Oncolytic 
viruses were initially used in the hope that they would 
have a direct oncolytic effect, killing tumor cells due to 
their massive replication. However, it then became clear 
that the essential anti-tumoral effects of these viruses 
were not direct. They were instead due to the immune 
response triggered by their presence (for a review, see 
[44]). However, treatments with oncolytic viruses have 
present limits, which need to be analyzed. These viruses 
often have a modest anti-tumor effect because they fail 
to spread properly within the tumor. Furthermore, the 
efficacy of the immune system against viruses is such that 
the virus-induced response is rapidly extinguished. For 
instance, in a clinical trial performed with adenoviruses 
expressing melanoma-associated antigens, the results 
were disappointing, possibly because anti-viral antibodies 
were present before vaccination, blunting its effects [45]. 
Nevertheless, the first oncolytic virus therapy for the 
treatment of melanoma lesions had been FDA-approved 
in october 2015 (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm469571.html).
In addition to the use of controlled pathogens, 
we could design artificial ways of mimicking a local 
viral attack, for tumors in appropriate locations, with 
the goal of simultaneously activating multiple actors 
of the immune system. We have recently applied this 
strategy in an implanted tumor model in mice. We used 
a compound vaccine aimed to trigger simultaneous Mφ 
and T-cell responses [46]. The vaccine, injected into the 
tissues adjoining the tumor, included IFNα to trigger an 
anti-viral response, and a tumor antigen targeted to DC 
through its chimerization with a Shiga toxin. In this 
model, tumor regression was observed in nearly all cases, 
whereas the two components of the vaccine were almost 
totally ineffective when used in isolation. We obtained 
several lines of evidence suggesting that both Mφ and 
T cells were required for this effect. Their interactions 
were complex, and each of these cell types can be seen 
as acting both upstream and downstream of the other. 
Following vaccination, the Mφ arrive first and are 
required for the subsequent recruitment of large numbers 
of T cells, as in the anti-infectious response. Conversely, 
the few T cells arriving with the Mφ are required for Mφ 
activation. However, after a few days of strong tumor 
regression, some of the tumors begin to grow again. This 
should be seen as a normal outcome, corresponding to 
the usual phase of immune response inactivation. We are 
now analyzing the principal mechanisms at work during 
this secondary growth, and ways of inhibiting them at 
appropriate time points.
What next?
Obviously, it is easier to treat implanted tumors 
in mice than to treat oncogene-induced murine tumors, 
and the extension of these results from mice to men 
will constitute another major hurdle. However, a few 
simple principles proposed a few years ago [47], further 
developed in this paper, should make it possible to 
improve immunotherapies for cancer. These principles can 
be summarized as follows.
First, efficient immune responses are those 
that have been selected on the basis of their efficacy 
against pathogens, during the course of evolution. They 
are never mediated by a single type of cells, instead 
systematically requiring complex cooperation between 
multiple cell types. When applying this notion to cancer 
immunotherapy, it may be helpful to think in terms of 
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dynamic cellular networks. On the one hand, there is the 
tumor ecosystem, including tumor and stromal cells; on 
the other, the immune infiltrate. If we wish to destabilize 
the tumor ecosystem, it is highly desirable to attack a 
number of different points simultaneously and to stimulate 
the immune infiltrate at several levels.
Second, efficient immune responses are usually of a 
blitzkrieg type. At the scale of an organism, anti-infectious 
responses last a few days, if there is no uncontrolled 
complication, and are always followed by inactivation 
phases that must be dealt with. The transient nature of 
immune responses is necessary to avoid autoimmunity. 
The question of kinetics is also important for 
the analysis of intra-tumoral immune infiltrates. Such 
analyses, performed in resected tumors, are widely used 
for prognosis purposes. One should keep in mind that the 
detailed nature of an immune infiltrate in a growing tumor 
provides a snapshot of an immune response that has failed 
to control the tumor. It does not include any information 
about the kinetics of the response. It can provide elements 
related to the initial spontaneous response, but it yields 
no insight into the nature of an efficient anti-tumoral 
response. This highlights the importance, whenever 
possible, of analyzing in detail the kinetics of efficient 
anti-immune responses associated with tumor regression 
[48].
Here are a couple of examples of how these 
notions could be better used in combined therapies. The 
first example concerns therapies based on CAR T cells. 
As explained above, one of the reasons for the failure 
of these treatments against solid tumors is the lack of 
specificity of these T cells, resulting in off-target effects 
and excessive toxicity [49]. This problem is mostly treated 
with corticosteroids or other anti-inflammatory molecules. 
However, simply limiting the intensity of the attack cannot 
improve its specificity. It is not surprising that attempts 
to mount an immune response based entirely on T cells, 
without aiming at stimulating other partners, have to 
involve a violent T-cell response, which may turn out to be 
poorly controlled. The risk is further increased by attempts 
to use CAR T cells in which PD-1 and CTLA-4 have 
been knocked out. Why not aim to achieve cooperation 
between local inflammation at the level of the tumor and 
smaller numbers of CAR T cells? Local inflammation can 
be achieved with oncolytic viruses or by the peritumoral 
injection of IFNα. Such local signals might favor the 
recruitment of circulating activated T cells, as in our 
murine model [48]. We have observed that efficiency of 
local inflammation elicited by IFNα was much larger than 
that elicited by systemic IFNα. A comparison with anti-
infectious responses helps to understand that the induction 
of local inflammation is more likely to be successful than 
the systemic use of IFNα more commonly used. The logic 
at work in such a proposal is diametrically opposed to that 
underlying the combination of a large dose of CAR T cells 
with corticosteroids.
Second example: despite the spectacular results 
achieved with anti-PD-1 and anti-CTLA-4 therapies, these 
approaches do not take into account the transient nature of 
efficient immune responses. Anti-PD-1 and anti-CTLA-4 
antibodies aim at reducing inhibitory mechanisms in T 
cells, limiting the strength of the inactivation phase, but 
they ignore the activation phase. Such treatments would 
be greatly improved by the introduction of a prior phase 
of deliberately triggered activation, mimicking a local 
response to infection, for example. An effective way of 
achieving this end would be to combine the action of 
oncolytic viruses with an anti-PD-1 approach [50]. 
In conclusion, if there is no magic cancer 
immunotherapy, a few basic but overlooked principles 
could help the design of more efficient immunotherapies. 
They are summarized a last time.
Anti-infectious immune responses are based on cell-
cell cooperations. Given their high efficacy, they should be 
used as templates for anti-tumoral responses, and include 
multiple simultaneous stimuli. 
Efficient anti-infectious immune responses are 
biphasic, and the importance of such kinetics must be 
taken into account.
Examples of applications of these principles have 
been presented above. Such notions are at odds with the 
principles often applied in clinical trials, which usually 
start with a dose escalation, to adjust the intensity of 
the blow judged in terms of efficacy/toxicity ratio, but 
which pay much less attention to the context in which 
this blow is delivered. In this perspective, we hope that 
the reasoning outlined here will be of value, and will 
encourage different, hopefully successful approaches.
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